Loading...
Loading...
DBVT| Name | Value |
|---|---|
| Revenues | 1.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 1.2M |
| Operating Expense | 35.0M |
| Operating I/L | -33.8M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.7M |
| Pretax | -33.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -33.1M |
DBV Technologies S.A. is a clinical-stage biopharmaceutical company specializing in epicutaneous immunotherapy products. Its lead product, Viaskin Peanut, has completed Phase III clinical trials for peanut allergy treatment. The company is also developing Viaskin Milk and Viaskin Egg for cow's milk protein allergy and hen's egg allergy, respectively. Additionally, DBV Technologies is working on a booster vaccine for Bordetella pertussis and has research programs for respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. The company generates revenue through the development and commercialization of its immunotherapy products and diagnostic collaborations, such as the partnership with Nestlé Health Science for the MAG1C atopy patch test.
